San Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.”
The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.